Evaxion Advances EVX-V1 CMV Vaccine Program With New Data Demonstrating Protective Effects Of Novel AI-Discovered Antigens

Evaxion A/S announced progress in its EVX-V1 cytomegalovirus (CMV) vaccine program, reporting new data that shows protective effects of the lead antigens developed through the company’s AI-Immunology™ platform. The findings support the potential of Evaxion’s AI-powered discovery approach to identify previously unknown CMV vaccine targets.

Using its proprietary technology, Evaxion has uncovered novel CMV antigens that trigger targeted immune responses and reduce viral infection and cell-to-cell spread in both cellular and animal models. These discoveries are considered significant given the limited number of protective CMV antigens identified despite decades of research.

The company stated that the new data builds upon earlier findings showing that its enhanced pre-fusion glycoprotein B antigen effectively neutralizes CMV. This optimized gB antigen forms a central part of the multi-component EVX-V1 vaccine, which integrates both AI-discovered and AI-enhanced antigens to improve broad immune protection.

Evaxion is continuing preclinical development of EVX-V1, including further antigen optimization, and is actively pursuing potential partnerships to accelerate the vaccine’s transition into clinical studies. Leadership expressed optimism that AI-driven innovation may lead to transformative progress in preventing CMV, an area with substantial unmet need.